Search results for "Preserved ejection fraction"

showing 10 items of 43 documents

Entrenamiento de la musculatura inspiratoria y la electroestimulación muscular funcional en el tratamiento de la insuficiencia cardiaca con función s…

2019

SEC 2017: Congreso de las Enfermedades Cardiovasculares Introducción y objetivos No se dispone de tratamientos farmacológicos que demuestren reducir la morbimortalidad asociada en pacientes con insuficiencia cardiaca y función sistólica conservada (IC-FEc). El objetivo del presente estudio fue evaluar si en pacientes con IC-FEc, el entrenamiento de la musculatura inspiratoria (EMI), la electroestimulación muscular funcional (EMF) o la combinación de ambas (EMI + EMF) puede mejorar la capacidad funcional, calidad de vida, parámetros de disfunción diastólica o biomarcadores a las 12 y 24 semanas. Métodos Un total de 61 pacientes estables con IC-FEc (clase funcional de la New York Heart Associ…

heart failure with preserved ejection fractioncapacidad funcionalbusiness.industry030204 cardiovascular system & hematologyinsuficiencia cardiaca con función sistólica conservadaexercise capacity03 medical and health sciences0302 clinical medicinequality of lifecalidad de vidaMedicinephysical therapyCardiology and Cardiovascular MedicinebusinessHumanitiesterapia físicaRevista Española de Cardiología
researchProduct

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach.

2020

International audience; To better understand heart failure with preserved ejection fraction (HFpEF), we need to better characterize the transition from asymptomatic pre-HFpEF to symptomatic HFpEF. The current emphasis on left ventricular diastolic dysfunction must be redirected to microvascular inflammation and endothelial dysfunction that leads to cardiomyocyte remodeling and enhanced interstitial collagen deposition. A pre-HFpEF patient lacks signs or symptoms of heart failure (HF), has preserved left ventricular ejection fraction (LVEF) with incipient structural changes similar to HFpEF, and possesses elevated biomarkers of cardiac dysfunction. The transition from pre-HFpEF to symptomati…

heart failure with preserved ejection fractionmedicine.medical_specialtylcsh:MedicineReviewCardiorenal syndromeright ventricle030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systempulmonary arterymedicine.arteryInternal medicineMedicine030212 general & internal medicineEjection fractionbusiness.industrylcsh:Rrenal functionGeneral Medicinemedicine.diseasePulmonary hypertension[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthmedicine.anatomical_structureinflammationVentricleHeart failurePulmonary arteryCardiologycardiovascular systemmedicine.symptomHeart failure with preserved ejection fractionbusinessatrial failure heart failure with preserved ejection fraction inflammation pulmonary artery renal function right ventricleatrial failure
researchProduct

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction

2020

Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP &ge

heart failure with preserved ejection fractionmedicine.medical_specialtylcsh:Medicinerisk stratification030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterymedicine030212 general & internal medicineStage (cooking)right ventricularStaging systemRisk stratificationRight ventricularbusiness.industryMortality ratelcsh:RGeneral Medicinemedicine.diseaseBlood pressureHeart failure with preserved ejection fractionHeart failurePulmonary arteryRisk stratificationCardiologybusinessHeart failure with preserved ejection fraction
researchProduct

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

2021

Abstract   Rationale The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechanism of action of empagliflozin in HFpEF at the molecular level. Methods We retrieved information regarding HFpEF pathophysiological motifs and differentially expressed genes/proteins, together with empagliflozin target information and bioflags, from specialized publicly available databases. Artificial neural networks and deep learning AI were used to model the molecular effec…

medicine.medical_specialtyAction (philosophy)business.industryInternal medicineEmpagliflozinmedicineMolecular mechanismCardiologyCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionDecoding methodsEuropean Heart Journal
researchProduct

Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients

2021

Abstract Aims Recent guidelines recommend a systolic blood pressure (SBP) target below 130 mmHg in heart failure patients with preserved ejection fraction (HFpEF), whatever their age. We investigated whether this intensive SBP control was associated with better survival in very old adults hospitalized for acute HFpEF. Methods and results We conducted an observational study in an acute geriatric unit: all consecutive patients discharged from hospital for acute heart failure from 1 March 2019 to 29 February 2020 with a diagnosis of HFpEF were included. Re‐hospitalization and all‐cause mortality at 1 year were compared according to the mean SBP at discharge (patients with a mean SBP < 130 mmHg…

medicine.medical_specialtyBlood PressureVentricular Function LeftElderlyInternal medicineRe‐hospitalizationDiseases of the circulatory (Cardiovascular) systemHumansMedicineMortalityMedical prescriptionProspective cohort studyAgedAged 80 and overHeart FailureEjection fractionbusiness.industryHazard ratioStroke VolumeOriginal ArticlesPreserved ejection fractionPrognosismedicine.diseaseConfidence intervalBlood pressureRC666-701Heart failureSystolic blood pressureCardiologyOriginal ArticleCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct

Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in long-term survivors: a long-term prospective longit…

2019

Background: Long-term trajectories of left ventricular ejection fraction (LVEF) in heart failure (HF) patients with preserved EF (HFpEF) remain unclear. Our objective was to assess long-term longitudinal trajectories in consecutive HFpEF patients and the prognostic impact of LVEF dynamic changes over time. Methods and Results: Consecutive ambulatory HFpEF patients admitted to a multidisciplinary HF Unit were prospectively evaluated by 2-dimensional echocardiography at baseline and at 1, 3, 5, 7, 9, and 11 years of follow-up. Exclusion criteria were patients having a previous known LVEF &lt;50%, patients undergoing only 1 echocardiogram study, and those with a diagnosis of dilated, noncompa…

medicine.medical_specialtyEjection fractionVentricular functionbusiness.industryFollow up studiesHeart failureInsuficiència cardíacamedicine.disease:Informàtica [Àrees temàtiques de la UPC]Heart failureInternal medicineCardiologymedicinecardiovascular systemcardiovascular diseasesCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinesscirculatory and respiratory physiology
researchProduct

Clinical utility of cardiopulmonary exercise testing in patients with heart failure with preserved ejection fraction

2017

medicine.medical_specialtyEjection fractionbusiness.industryCardiopulmonary exercise testingStroke volume030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineInternal medicineHeart failuremedicineCardiologyIn patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionEuropean Journal of Heart Failure
researchProduct

Physical therapy in heart failure with preserved ejection fraction: A systematic review.

2014

About 50% of patients with heart failure (HF) have preserved ejection fraction (HFpEF) which is especially common in elderly people with highly prevalent co-morbid conditions. HFpEF is usually defined as an ejection fraction equal to or greater than 50%, although some studies have used a limit as low as 40%. The prevalence of this syndrome is expected to increase over the next decades. The associated impact on mortality and hospital readmissions has made of this entity a major public health issue. Despite the fact that mortality and re-hospitalisation rates of HFpEF are similar to the syndrome of HF with reduced ejection fraction (HFrEF), currently there is no available evidence-based thera…

medicine.medical_specialtyEpidemiologyExercise intoleranceComorbidity030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicinemedicinePrevalenceElderly peopleHumans030212 general & internal medicineIntensive care medicinePhysical Therapy ModalitiesHeart FailureEjection fractionExercise ToleranceSurrogate endpointbusiness.industryStroke VolumeRecovery of FunctionExercise capacitymedicine.diseaseTreatment OutcomeHeart failureCardiologyQuality of Lifemedicine.symptomCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionEuropean journal of preventive cardiology
researchProduct

Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: Rationale and Stud…

2016

Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent form of heart failure in developed countries. Regrettably, there is no evidence-based effective therapy for HFpEF. We seek to evaluate whether inspiratory muscle training, functional electrical stimulation, or a combination of both can improve exercise capacity as well as left ventricular diastolic function, biomarker profile, quality of life (QoL), and prognosis in patients with HFpEF. A total of 60 stable symptomatic patients with HFpEF (New York Heart Association class II-III/IV) will be randomized (1:1:1:1) to receive a 12-week program of inspiratory muscle training, functional electrical stimulation, a…

medicine.medical_specialtyNew York Heart Association Classbusiness.industryGeneral MedicineStroke volume030204 cardiovascular system & hematologymedicine.diseaselaw.invention03 medical and health sciences0302 clinical medicineQuality of lifeRandomized controlled triallawHeart failureClinical endpointPhysical therapyMedicine030212 general & internal medicineCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionProspective cohort studybusinessClinical Cardiology
researchProduct

Right ventricular function and iron deficiency in acute heart failure

2021

Abstract Aims Iron deficiency (ID) is a frequent finding in patients with chronic and acute heart failure (AHF) along the full spectrum of left ventricular ejection fraction (LVEF). Iron deficiency has been related to ventricular systolic dysfunction, but its role in right ventricular function has not been evaluated. We sought to evaluate whether ID identifies patients with greater right ventricular dysfunction in the setting of AHF. Methods and results We prospectively included 903 patients admitted with AHF. Right systolic function was evaluated by tricuspid annular plane systolic excursion (TAPSE) and the ratio TAPSE/pulmonary artery systolic pressure (TAPSE/PASP). Iron deficiency was de…

medicine.medical_specialtyVentricular Dysfunction Right030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVentricular Function Left03 medical and health sciences0302 clinical medicineLeft ventricle ejection fraction[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineSystoleAgedAged 80 and overHeart FailureIron deficiency.Ejection fractionAnemia Iron-DeficiencybiologyTransferrin saturationbusiness.industryIron deficiencyRight ventricle ejection fractionStroke VolumeGeneral MedicineMiddle AgedPrognosismedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTricuspid annular plane systolic excursionFerritinBlood pressureHeart failureVentricular Function Rightbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusiness
researchProduct